Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003))

T. Bachelot; F. Dalenc; S. Chabaud; P. Cottu; D. Allouache; E. Brain; J. P. Jacquin; J. Grenier; L. Venat Bouvet; M. Brunt; M. Campone; F. Del Piano; M. Debled; A. C. Hardy Bessard; S. Giacchetti; J. Bliss; J. L. Canon; J. Lemonnier; D. Cameron; F. André

doi:10.1016/j.annonc.2021.04.004

Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003))

T. Bachelot, F. Dalenc, S. Chabaud, P. Cottu, D. Allouache, E. Brain, J. P. Jacquin, J. Grenier, L. Venat Bouvet, M. Brunt, M. Campone, F. Del Piano, M. Debled, A. C. Hardy Bessard, S. Giacchetti, J. Bliss, J. L. Canon, J. Lemonnier, D. Cameron, F. André

Research output: Contribution to journal › Comment/debate

Abstract

The organisers regret that the abstract publication number was omitted from the title of the original publication of this abstract. The title with the abstract publication number is as follows: VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer The organisers would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	820
Number of pages	1
Journal	Annals of Oncology
Volume	32
Issue number	6
DOIs	https://doi.org/10.1016/j.annonc.2021.04.004
Publication status	Published - 1 Jun 2021

Access to Document

10.1016/j.annonc.2021.04.004

Cite this

Bachelot, T., Dalenc, F., Chabaud, S., Cottu, P., Allouache, D., Brain, E., Jacquin, J. P., Grenier, J., Venat Bouvet, L., Brunt, M., Campone, M., Del Piano, F., Debled, M., Hardy Bessard, A. C., Giacchetti, S., Bliss, J., Canon, J. L., Lemonnier, J., Cameron, D., & André, F. (2021). Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003)). Annals of Oncology, 32(6), 820. https://doi.org/10.1016/j.annonc.2021.04.004

@article{80fcc703ea4f4ebaad1c6b7de2c62124,

title = "Corrigendum to {\textquoteleft}VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer{\textquoteright} (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003))",

abstract = "The organisers regret that the abstract publication number was omitted from the title of the original publication of this abstract. The title with the abstract publication number is as follows: VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer The organisers would like to apologise for any inconvenience caused.",

author = "T. Bachelot and F. Dalenc and S. Chabaud and P. Cottu and D. Allouache and E. Brain and Jacquin, {J. P.} and J. Grenier and {Venat Bouvet}, L. and M. Brunt and M. Campone and {Del Piano}, F. and M. Debled and {Hardy Bessard}, {A. C.} and S. Giacchetti and J. Bliss and Canon, {J. L.} and J. Lemonnier and D. Cameron and F. Andr{\'e}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jun,

day = "1",

doi = "10.1016/j.annonc.2021.04.004",

language = "English",

volume = "32",

pages = "820",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "6",

}

Bachelot, T, Dalenc, F, Chabaud, S, Cottu, P, Allouache, D, Brain, E, Jacquin, JP, Grenier, J, Venat Bouvet, L, Brunt, M, Campone, M, Del Piano, F, Debled, M, Hardy Bessard, AC, Giacchetti, S, Bliss, J, Canon, JL, Lemonnier, J, Cameron, D & André, F 2021, 'Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003))', Annals of Oncology, vol. 32, no. 6, pp. 820. https://doi.org/10.1016/j.annonc.2021.04.004

Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003)). / Bachelot, T.; Dalenc, F.; Chabaud, S. et al.
In: Annals of Oncology, Vol. 32, No. 6, 01.06.2021, p. 820.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to ‘VP1-2021

T2 - Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003))

AU - Bachelot, T.

AU - Dalenc, F.

AU - Chabaud, S.

AU - Cottu, P.

AU - Allouache, D.

AU - Brain, E.

AU - Jacquin, J. P.

AU - Grenier, J.

AU - Venat Bouvet, L.

AU - Brunt, M.

AU - Campone, M.

AU - Del Piano, F.

AU - Debled, M.

AU - Hardy Bessard, A. C.

AU - Giacchetti, S.

AU - Bliss, J.

AU - Canon, J. L.

AU - Lemonnier, J.

AU - Cameron, D.

AU - André, F.

PY - 2021/6/1

Y1 - 2021/6/1

N2 - The organisers regret that the abstract publication number was omitted from the title of the original publication of this abstract. The title with the abstract publication number is as follows: VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer The organisers would like to apologise for any inconvenience caused.

AB - The organisers regret that the abstract publication number was omitted from the title of the original publication of this abstract. The title with the abstract publication number is as follows: VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer The organisers would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85104644309&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.04.004

DO - 10.1016/j.annonc.2021.04.004

M3 - Comment/debate

AN - SCOPUS:85104644309

SN - 0923-7534

VL - 32

SP - 820

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -

Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (Annals of Oncology (2021) 32(4) (574–575), (S0923753421001071), (10.1016/j.annonc.2021.02.003))

Abstract

Access to Document

Other files and links

Cite this